Altered strain of the modified vaccinia virus ankara (MVA)
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
Jan 27, 2004
Grant Date -
Jan 16, 2003
app pub date -
Aug 22, 2002
filing date -
Mar 14, 2000
priority date (Note) -
Expired
status (Latency Note)
Importance
Abstract
The invention provides new strains of the Modified Vaccinia Virus Ankara (MVA) that have a strongly reduced virulence for most mammals, especially humans, but nevertheless grows in cells of a continuous cell line approved for the production of a therapeutic agent such as a vaccine. The invention also provides a method for producing said adapted MVA strains. The adapted MVA can be used e.g. for parenteral immunization, as a vector system, or in the active or inactivated from as an adjuvant or as a regulator of the unspecific components of the immune system.
First Claim
Family
International Classification(s)
- [Classification Symbol]
- [Patents Count]
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully